- Home
- EAF vs ENGN Comparison
EAF vs ENGN Comparison
Compare EAF & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | EAF | ENGN |
|---|---|---|
| Founded | 1886 | 1999 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | |
| Sector | Energy | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 332.0M | 379.3M |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | EAF | ENGN |
|---|---|---|
| Price | $15.93 | $9.07 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 7 |
| Target Price | $14.25 | ★ $22.71 |
| AVG Volume (30 Days) | 184.7K | ★ 273.2K |
| Earning Date | 02-06-2026 | 12-22-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $521,894,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $11.64 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.50 | $2.65 |
| 52 Week High | $20.32 | $11.14 |
Technical Indicators
Market Signals| Indicator | EAF | ENGN |
|---|---|---|
| Relative Strength Index (RSI) | 54.42 | 58.65 |
| Support Level | $13.91 | $7.57 |
| Resistance Level | $17.09 | $10.10 |
| Average True Range (ATR) | 1.09 | 0.74 |
| MACD | -0.05 | 0.09 |
| Stochastic Oscillator | 51.94 | 60.47 |
Price Performance
Historical ComparisonAbout EAF GrafTech International Ltd.
GrafTech International Ltd is a manufacturer of high-quality graphite electrode products essential to the production of EAF steel and other ferrous and non-ferrous metals. The company has only reportable segment, Industrial Materials, is comprised of its two product categories: graphite electrodes and petroleum needle coke products. Petroleum needle coke is key raw material used in the production of graphite electrodes.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.